Omixon is a global molecular diagnostics company headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research histocompatibility laboratories to bring the benefits of new technologies to improve transplant outcomes.
Omixon is transforming molecular biology innovations into state-of-the-art products in transplant diagnostics which could facilitate genetic testing solutions to transplant laboratories and transplant centers. Omixon uses its multidisciplinary competence ranging from bioinformatics, through software engineering to molecular diagnostics to design its products.
Omixon had the first successful commercial NGS-based HLA typing kit (Holotype HLA) and software (HLA Twin) in 2014. Holotype HLA that delivers the most accurate high-resolution HLA genotyping available and is used in more than 50+ hospitals worldwide.
Omixon’s research software, the HLA Explore analyses data both from short-read and long-read sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing data.
